Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

Published 2015 View Full Article

Authors

Keywords

Abiraterone acetate, Cabazitaxel, Castration-resistant prostate cancer, Enzalutamide, Fourth line, Prognostic factors, Third line

Journal

EUROPEAN UROLOGY

Volume 68, Issue 1, Pages 147-153

Publisher

Elsevier BV

Online

2014-10-25

DOI

10.1016/j.eururo.2014.10.014

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now